{{medical}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 458442916
| IUPAC_name = 5-chloro-1-(1-[3-(2-oxo-2,3-dihydro-1''H''-benzo[''d'']imidazol-1-yl)propyl]piperidin-4-yl)-1''H''-benzo[''d'']imidazol-2(3''H'')-one
| image = Domperidone structure.png
| image2 = Domperidone_3D.png

<!--Clinical data-->
| tradename = Motilium
| Drugs.com = {{drugs.com|CONS|domperidone}}
| pregnancy_category = Not classified (US)
| legal_status = Not approved for use or sale: US; prescription medicine (POM): India, Australia, Canada, Israel, Belgium; Over the Counter (OTC): UK (Prescription Only Medicine as of 4th September 2014), Egypt, Ireland, Italy, Japan, Netherlands, South Africa, Switzerland, China, Russia, Slovakia, Thailand, Malta, South Korea, and Romania<ref>{{cite web |url=http://www.medsafe.govt.nz/downloads/MCC34Domperidone.doc |title=Domperidone |accessdate=2013-06-30 |deadurl=yes |archiveurl=https://web.archive.org/web/20130522022543/http://www.medsafe.govt.nz/downloads/MCC34Domperidone.doc |archivedate=2013-05-22 }}</ref>
| routes_of_administration = Oral, [[intravenous_therapy|intravenous]], rectal

<!--Pharmacokinetic data-->
| bioavailability = High
| protein_bound = 91–93%
| metabolism = [[Liver|Hepatic]] and [[Intestine|intestinal]] ([[First_pass_effect|first-pass]])
| elimination_half-life = 7 hours
| excretion = Breast milk, renal

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 57808-66-9
| ATC_prefix = A03
| ATC_suffix = FA03
| ATC_supplemental = {{ATCvet|P51|AX24}}
| PubChem = 3151
| IUPHAR_ligand = 965
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB01184
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3039
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5587267Z69
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01745
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 31515
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 219916

<!--Chemical data-->
| C=22 | H=24 | Cl=1 | N=5 | O=2 
| molecular_weight = 425.911 g/mol
| smiles = Clc1cc2c(cc1)N(C(=O)N2)C5CCN(CCCN4c3ccccc3NC4=O)CC5
| InChI = 1/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)
| InChIKey = FGXWKSZFVQUSTL-UHFFFAOYAW
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = FGXWKSZFVQUSTL-UHFFFAOYSA-N
}}
'''多潘立酮'''（Domperidone），商品名為'''嗎丁啉'''（Motilium），是一种[[口服|口服]]和[[静脉注射|静脉注射]]用的抗[[多巴胺|多巴胺]]类药物，一般用以抑制[[恶心|恶心]]和[[呕吐|呕吐]]，有时也用于促进[[乳汁|乳汁]]分泌。

多潘立酮的抗催吐作用主要是由于其对外周多巴胺受体的拮抗作用，直接作用于胃肠壁，可增加食道下部括约肌张力，增强胃蠕动，促进胃排空，协调胃与十二指肠运动。

催乳作用主要是由于其刺激[[脑垂体|脑垂体]][[催乳激素|催乳激素]]的释放。

==不良反应==
本品已知的不良作用包括：
心脏QTc延长,有室性心律不齐的风险。在欧洲进行的一项基于2014年新报告的严重心脏副作用的案例的研究发现，服用多潘立酮与严重心律失常，QTc延长，尖锐度心动过速和心源性猝死的风险增加有关。
*[[过敏反应|过敏反应]]（极罕见）
*[[锥体外系|锥体外系]]副作用（极罕见）
*皮疹（极罕见）
*胃肠道不适（罕见）
*[[溢乳|溢乳]]（罕见）
*男子乳房女性化（罕见）
*闭经（罕见）
*一过性胃肠痉挛（罕见）


{{功能性胃肠疾病治疗药物}}
{{止吐剂}}

[[Category:止吐劑|Category:止吐劑]]
[[Category:哌啶|Category:哌啶]]
[[Category:苯并咪唑|Category:苯并咪唑]]
[[Category:脲|Category:脲]]
[[Category:有机氯化合物|Category:有机氯化合物]]